Sam Brusco, Associate Editor09.28.23
Acuitive Technologies has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its CITRELOCK DUO fixation device for biceps tenodesis (biceps tendon tears caused by injury or overuse). CITRELOCK DUO features, according to Acuitive, a tendon-friendly spiral thread made from its next-gen resorbable material.
CITRELOCK DUO’s biomimetic material composition matches native bone’s inorganic content, and its soft spiral thread design was designed to prevent tendon laceration. Its compressive strength mimics cortical bone and has a modulus similar to trabecular bone and the material’s elastomeric properties aim to improve pull-out strength.
The material’s controlled resorption rate seeks to mitigate post-operative chronic inflammation.
“Our customers are looking for a fixation device with unique mechanical properties that protects the tendon’s integrity during insertion while providing improved fixation within the bone tunnel. Additionally, the CITRELOCK DUO provides more predictable resorption while avoiding the chronic inflammation reported with other biodegradable polymers. With its innovative CITREGEN material technology and unique thread design, the CITRELOCK DUO fills the clinical need surgeons have been seeking,” Acuitive’s VP of product development Rui Ferreira told the press.
CITRELOCK DUO is the second of a series of new sports medicine products the company said it plans to release. Acuitive announced the first surgical use of its Citrelock ACL tendon fixation device in June 2023.
CITRELOCK DUO’s biomimetic material composition matches native bone’s inorganic content, and its soft spiral thread design was designed to prevent tendon laceration. Its compressive strength mimics cortical bone and has a modulus similar to trabecular bone and the material’s elastomeric properties aim to improve pull-out strength.
The material’s controlled resorption rate seeks to mitigate post-operative chronic inflammation.
“Our customers are looking for a fixation device with unique mechanical properties that protects the tendon’s integrity during insertion while providing improved fixation within the bone tunnel. Additionally, the CITRELOCK DUO provides more predictable resorption while avoiding the chronic inflammation reported with other biodegradable polymers. With its innovative CITREGEN material technology and unique thread design, the CITRELOCK DUO fills the clinical need surgeons have been seeking,” Acuitive’s VP of product development Rui Ferreira told the press.
CITRELOCK DUO is the second of a series of new sports medicine products the company said it plans to release. Acuitive announced the first surgical use of its Citrelock ACL tendon fixation device in June 2023.